Top

Published in:

01-04-2016 | News item

FDA adding HF warnings to labels of alogliptin, saxagliptin

Published in: Reactions Weekly | Issue 1/2016

Excerpt

After completing a safety review on the risk of heart failure (HF) in patients receiving alogliptin- and saxagliptin-containing products, the US FDA is adding warnings on the risk of HF to labels of alogliptin (Nesina), alogliptin/metformin (Kazano), alogliptin/pioglitazone (Oseni), saxagliptin (Onglyza), and saxagliptin/metformin (Kombiglyze XR¹). …

extended-release

FDA. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Internet Document : 5 Apr 2016. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm

Title: FDA adding HF warnings to labels of alogliptin, saxagliptin
Publication date: 01-04-2016
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2016
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-016-16443-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

FDA adding HF warnings to labels of alogliptin, saxagliptin

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

Naproxen overdose

Imipenem/cilastatin

Mycophenolate mofetil

Carbamazepine overdose

Epinephrine

Bleomycin/cisplatin/etoposide